Xenon Pharmaceuticals Inc. Aktie News

The biotech sector is one that's become red-hot, at least in recent years. After around a decade of stagnation, investors appear to be intent on increasing their exposure to top biotech names in the market, as growth in other sectors of the economy have led to valuations that now look more elevated than the biotech sector (in many cases).

Innovative Trial Design to Directly Measure Microvascular Functional Effects of Inhaled Therapy at the Capillary level of Pulmonary Hypertension Patients with Interstitial Lung Disease (PH-ILD) Innovative Trial Design to Directly Measure Microvascular Functional Effects of Inhaled Therapy at the Capillary level of Pulmonary Hypertension Patients with Interstitial Lung Disease (PH-ILD)

VANCOUVER, British Columbia and BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to ten new non-officer employees consisting of an aggregate of 42...

Xenon Pharmaceuticals Inc. (XENE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

VANCOUVER, British Columbia and BOSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today outlined forward momentum across the Company's Phase 3 portfolio and discussed pipeline progress at t...

VANCOUVER, British Columbia and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at the 44th Annual J.P. Morgan Healthcare Conference, taking ...

Xenon Pharmaceuticals (XENE) is undervalued given azetukalner's late-stage potential to transform epilepsy and mood disorder treatment. XENE's $555M cash position supports operations into 2027, reducing near-term financing risk despite increased R&D and G&A expenses. Azetukalner's Phase 3 epilepsy and depression trials, strong long-term efficacy, and unique mechanism offer significant commercia...

Xenon Pharmaceuticals Inc. (XENE) Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation Transcript